Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2016, Article ID 2180765, 7 pages
http://dx.doi.org/10.1155/2016/2180765
Research Article

Serum Endocan Levels Associated with Hypertension and Loss of Renal Function in Pediatric Patients after Two Years from Renal Transplant

1Nephrology Division, School of Medicine, Federal University of São Paulo, São Paulo, SP, Brazil
2Pediatrics Department, School of Medicine, Federal University of São Paulo, São Paulo, SP, Brazil

Received 13 September 2016; Accepted 20 November 2016

Academic Editor: Laszlo Rosivall

Copyright © 2016 Livia Victorino de Souza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. A. Warady, D. Hébert, E. K. Sullivan, and S. R. Alexander, “Renal transplantation, chronic dialysis and chronic renal insufficiency in children and adolescents. The 1995 annual report of the North American Pediatric Renal Transplant Cooperative study,” Pediatric Nephrology, vol. 11, pp. 49–64, 1997. View at Google Scholar
  2. B. J. van der Heijden, P. C. W. van Dijk, K. Verrier-Jones, K. J. Jager, and J. D. Briggs, “Renal replacement therapy in children: data from 12 registries in Europe,” Pediatric Nephrology, vol. 19, no. 2, pp. 213–221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. P. McDonald and J. C. Craig, “Long-term survival of children with end-stage renal disease,” The New England Journal of Medicine, vol. 350, no. 26, pp. 2654–2662, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Mehrabi, A. Kashfi, B. Tönshoff et al., “Long-term results of paediatric kidney transplantation at the University of Heidelberg: a 35 year single-centre experience,” Nephrology Dialysis Transplantation, vol. 19, S4, pp. iv69–iv74, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Wigger, E. Drückler, J. Muscheites, and H. J. Stolpe, “Course of glomerular filtration rate after renal transplantation and the influence of hypertension,” Clinical Nephrology, vol. 56, no. 6, pp. S30–S34, 2001. View at Google Scholar · View at Scopus
  6. R. Büscher, U. Vester, A.-M. Wingen, and P. F. Hoyer, “Pathomechanisms and the diagnosis of arterial hypertension in pediatric renal allograft recipients,” Pediatric Nephrology, vol. 19, no. 11, pp. 1202–1211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Seeman, “Hypertension after renal transplantation,” Pediatric Nephrology, vol. 24, no. 5, pp. 959–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Opelz, T. Wujciak, and E. Ritz, “Association of chronic kidney graft failure with recipient blood pressure,” Kidney International, vol. 53, no. 1, pp. 217–222, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Moudgil, K. Martz, D. M. Stablein, and D. P. Puliyanda, “Variables affecting estimated glomerular filtration rate after renal transplantation in children: a NAPRTCS data analysis,” Pediatric Transplantation, vol. 14, no. 2, pp. 288–294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. M. Mitsnefes, P. R. Khoury, and P. T. McEnery, “Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients,” Journal of Pediatrics, vol. 143, no. 1, pp. 98–103, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. J. W. Groothoff, K. Cransberg, M. Offringa et al., “Long-term follow-up of renal transplantation in children: a Dutch cohort study,” Transplantation, vol. 78, no. 3, pp. 453–460, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Afsar, M. Takir, O. Kostek, A. Covic, and M. Kanbay, “Endocan: a new molecule playing a role in the development of hypertension and chronic kidney disease?” Journal of Clinical Hypertension, vol. 16, no. 12, pp. 914–916, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. M. I. Yilmaz, D. Siriopol, M. Saglam et al., “Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease,” Kidney International, vol. 86, no. 6, pp. 1213–1220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. H. G. Lee, H. Y. Choi, and J. Bae, “Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease,” Kidney International, vol. 86, no. 6, pp. 1079–1081, 2014. View at Publisher · View at Google Scholar
  15. D. Béchard, T. Gentina, M. Delehedde et al., “Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity,” The Journal of Biological Chemistry, vol. 276, no. 51, pp. 48341–48349, 2001. View at Google Scholar · View at Scopus
  16. S. M. Zhang, L. Zuo, Q. Zhou et al., “Expression and distribution of endocan in human tissues,” Biotechnic and Histochemistry, vol. 87, no. 3, pp. 172–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Lassalle, S. Molet, A. Janin et al., “ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines,” The Journal of Biological Chemistry, vol. 271, no. 34, pp. 20458–20464, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Balta, D. P. Mikhailidis, S. Demirkol, C. Ozturk, T. Celik, and A. Iyisoy, “Endocan: a novel inflammatory indicator in cardiovascular disease?” Atherosclerosis, vol. 243, no. 1, pp. 339–343, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Balta, D. P. Mikhailidis, S. Demirkol et al., “Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study,” Angiology, vol. 65, no. 9, pp. 773–777, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, “The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents,” Pediatrics, vol. 114, supplement 2, pp. 1–22, 2004. View at Google Scholar
  21. G. J. Schwartz and D. F. Work, “Measurement and estimation of GFR in children and adolescents,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 11, pp. 1832–1843, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. S. Levey, J. Coresh, E. Balk et al., “National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” Annals of Internal Medicine, vol. 139, no. 2, pp. 137–147, 2003. View at Publisher · View at Google Scholar
  23. M. A. Cikrikcioglu, Z. Erturk, E. Kilic et al., “Endocan and albuminuria in type 2 diabetes mellitus,” Renal Failure, pp. 1–7, 2016. View at Publisher · View at Google Scholar
  24. S. Li, L. Wang, C. Wang et al., “Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation,” Urology, vol. 80, no. 3, pp. 738.e1–738.e8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-H. Su, K.-H. Shu, C.-P. Hu et al., “Serum endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients,” Transplantation Proceedings, vol. 46, no. 2, pp. 323–327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. C. A. Peralta, D. R. Jacobs Jr., R. Katz et al., “Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR >60 mL/min/1.73 m2: the multi-ethnic study of atherosclerosis (MESA),” American Journal of Kidney Diseases, vol. 59, no. 1, pp. 41–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. L. M. Carrillo, E. Arciniegas, H. Rojas, and R. Ramírez, “Immunolocalization of endocan during the endothelial-mesenchymal transition process,” European Journal of Histochemistry, vol. 55, article e13, 2011. View at Google Scholar · View at Scopus
  28. M. Delehedde, L. Devenyns, C.-A. Maurage, and R. R. Vivès, “Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan,” International Journal of Cell Biology, vol. 2013, Article ID 705027, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Icli, E. Cure, M. C. Cure et al., “Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus,” Angiology, vol. 67, no. 8, pp. 749–755, 2016. View at Publisher · View at Google Scholar
  30. N. Altintas, L. C. Mutlu, D. C. Akkoyun et al., “Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea,” Angiology, vol. 67, no. 4, pp. 364–374, 2016. View at Publisher · View at Google Scholar
  31. Y. H. Lee, J. S. Kim, S. Kim et al., “Plasma endocan level and prognosis of immunoglobulin A nephropathy,” Kidney Research and Clinical Practice, vol. 35, no. 3, pp. 152–159, 2016. View at Publisher · View at Google Scholar
  32. T. Celik, S. Balta, M. Karaman et al., “Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan,” Blood Pressure, vol. 24, no. 1, pp. 55–60, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Menon, O. N. Kocher, and W. C. Aird, “Endothelial cell specific molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration,” Circulation, vol. 124, Article ID A15455, 2011. View at Google Scholar